Oncology and Hematology

Episodes 17-32 of 128

• 

  RestartResume

  Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma

  RestartResume

  Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma

  MinuteCE®

  Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma

  1.00 program credit

  • 

    

    Paolo A. Ascierto, MD

  • 

    

    Hussein Tawbi, MD, PhD

  1.00 program credit

• 

  RestartResume

  Novel Therapies in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

  RestartResume

  Novel Therapies in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

  MinuteCE®

  Novel Therapies in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

  1.25 program credits

  • 

    

    Stephen Liu, MD

  • 

    

    Joshua K. Sabari, MD

  • 

    

    Susan Scott, MD

  1.25 program credits

• 

  RestartResume

  Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma

  RestartResume

  Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma

  MinuteCE®

  Clinical Data Prompting Guideline Updates for Subcutaneous ICIs in Melanoma

  1.00 program credit

  • 

    

    Hussein Tawbi, MD, PhD

  • 

    

    Sapna Patel, MD

  1.00 program credit

• 

  RestartResume

  Strategies in EGFR-mutated Unresectable Stage III NSCLC

  RestartResume

  Strategies in EGFR-mutated Unresectable Stage III NSCLC

  MinuteCE®

  Strategies in EGFR-mutated Unresectable Stage III NSCLC

  1.25 program credits

  • 

    

    Stephen Liu, MD

  • 

    

    Joshua K. Sabari, MD

  • 

    

    Susan Scott, MD

  1.25 program credits

• 

  RestartResume

  Updates in Limited-Stage Small Cell Lung Cancer (LS-SCLC)

  RestartResume

  Updates in Limited-Stage Small Cell Lung Cancer (LS-SCLC)

  MinuteCE®

  Updates in Limited-Stage Small Cell Lung Cancer (LS-SCLC)

  1.25 program credits

  • 

    

    Stephen Liu, MD

  • 

    

    Joshua K. Sabari, MD

  • 

    

    Susan Scott, MD

  1.25 program credits

• 

  RestartResume

  Finding the Optimal Treatment for EGFR-mutated Metastatic NSCLC

  RestartResume

  Finding the Optimal Treatment for EGFR-mutated Metastatic NSCLC

  MinuteCE®

  Finding the Optimal Treatment for EGFR-mutated Metastatic NSCLC

  1.25 program credits

  • 

    

    Stephen Liu, MD

  • 

    

    Joshua K. Sabari, MD

  • 

    

    Susan Scott, MD

  1.25 program credits

• 

  MinuteCE®

  Innovations in Oncology Learning Center: From Guidelines to Practice: Melanoma

  1.00 credit 10 episodes

  • 

    

    John M. Kirkwood, MD

  • 

    

    Paolo A. Ascierto, MD

  • 

    

    Hussein Tawbi, MD, PhD

  • 

    

    Sapna Patel, MD

  1.00 credit 10 episodes

• 

  RestartResume

  Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy

  RestartResume

  Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy

  CME/CE

  Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy

  0.50 credits

  • 

    

    Kevin Kalinsky MD, MS

  • 

    

    Komal Jhaveri, MD, FACP

  0.50 credits

• 

  MinuteCE®

  Chemotherapy Strategies in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

  0.25 credits 2 episodes

  • 

    

    Eileen O’Reilly, MD

  • 

    

    Efrat Dotan, MD

  0.25 credits 2 episodes

• 

  RestartResume

  HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)

  RestartResume

  HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)

  CME/CE

  HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)

  • 

    

    Fernando López-Ríos, MD, PhD

  • 

    

    Christian Rolfo, MD, PhD

  • 

    

    Charlie Gourley, MD, PhD

• 

  RestartResume

  Mutational Testing in mCRC: Methods and Data Driving Treatment Selection

  RestartResume

  Mutational Testing in mCRC: Methods and Data Driving Treatment Selection

  MinuteCE®

  Mutational Testing in mCRC: Methods and Data Driving Treatment Selection

  1.00 program credit

  • 

    

    Fortunato Ciardiello, MD, PhD

  • 

    

    Jenny Seligmann, MBChB, PhD

  1.00 program credit

• 

  RestartResume

  Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes    

  RestartResume

  Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes    

  MinuteCE®

  Proactive Adverse Effect Management in mCRC: Improving Tolerability to Optimize Patient Outcomes    

  1.00 program credit

  • 

    

    Fortunato Ciardiello, MD, PhD

  • 

    

    Jenny Seligmann, MBChB, PhD

  1.00 program credit

• 

  RestartResume

  From Guidelines to Practice: First-Line Treatment Choices in mCRC

  RestartResume

  From Guidelines to Practice: First-Line Treatment Choices in mCRC

  MinuteCE®

  From Guidelines to Practice: First-Line Treatment Choices in mCRC

  1.00 program credit

  • 

    

    Fortunato Ciardiello, MD, PhD

  • 

    

    Jenny Seligmann, MBChB, PhD

  1.00 program credit

• 

  RestartResume

  Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond

  RestartResume

  Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond

  MinuteCE®

  Defining the Standard of Care and Optimal Sequencing in BRAF-Mutant mCRC: Second Line and Beyond

  1.00 program credit

  • 

    

    Fortunato Ciardiello, MD, PhD

  • 

    

    Jenny Seligmann, MBChB, PhD

  1.00 program credit

• 

  RestartResume

  Antibody-Drug Conjugates in Bladder Cancer: Guideline Updates and Adverse Event Management

  RestartResume

  Antibody-Drug Conjugates in Bladder Cancer: Guideline Updates and Adverse Event Management

  CME/CE

  Antibody-Drug Conjugates in Bladder Cancer: Guideline Updates and Adverse Event Management

  0.50 credits

  • 

    

    Elizabeth R. Plimack, MD, MS, FASCO

  • 

    

    Shilpa Gupta, MD

  0.50 credits

• 

  RestartResume

  Collaborative Insights to Solve the Puzzle of Bladder Cancer

  RestartResume

  Collaborative Insights to Solve the Puzzle of Bladder Cancer

  CME/CE

  Collaborative Insights to Solve the Puzzle of Bladder Cancer

  1.00 credit

  • 

    

    Daniel P. Petrylak, MD

  • 

    

    Elizabeth R. Plimack, MD, MS, FASCO

  • 

    

    Evan Y. Yu, MD

  1.00 credit

• Previous
• 1
• 2
• 3
• 4
• …
• 7
• 8
• Next